상세정보
Export to Refworks부가기능
Accelerating the Development of Diagnostic Biomarkers and Mitigating Drugs for Radiation Injury with Quantitative Mass Spectrometry
상세 프로파일
| 자료유형 | 학위논문 |
|---|---|
| 서명/저자사항 | Accelerating the Development of Diagnostic Biomarkers and Mitigating Drugs for Radiation Injury with Quantitative Mass Spectrometry. |
| 개인저자 | Liu, Kate. |
| 단체저자명 | University of California, Los Angeles. Chemistry 0153. |
| 발행사항 | [S.l.]: University of California, Los Angeles., 2019. |
| 발행사항 | Ann Arbor: ProQuest Dissertations & Theses, 2019. |
| 형태사항 | 102 p. |
| 기본자료 저록 | Dissertations Abstracts International 81-04B. Dissertation Abstract International |
| ISBN | 9781687966216 |
| 학위논문주기 | Thesis (Ph.D.)--University of California, Los Angeles, 2019. |
| 일반주기 |
Source: Dissertations Abstracts International, Volume: 81-04, Section: B.
Advisor: Loo, Joseph A. |
| 이용제한사항 | This item must not be sold to any third party vendors. |
| 요약 | Nuclear and radiological terrorism is an on-going public health concern, but very few effective measures exist to assess the extent of the injury or counter the injuries from these potential attacks. In response to this need, the UCLA Center for Medical Countermeasures against Radiation (CMCR) has dedicated their research efforts on radiation biodosimetry and drug development. On the diagnostic side, existing biodosimetry is only able to provide a crude estimate of radiation exposure dose. More effective diagnostic tools are needed to confirm exposure and predict tissue-specific radiation injury progression. Towards this end, we aimed to develop protein biomarkers that can assess organ-specific radiation damage. Utilizing quantitative mass spectrometry (MS)-based proteomics, we performed discovery experiments to identify proteins that have desirable biomarker characteristics. In addition, we evaluated a set of hypothesized biomarker candidates as part of antioxidant response using a targeted MS method. On the treatment side, very few medical products are available to mitigate radiation-induced injury. In fact, only three radiomitigators, through drug repurposing, have been approved by the FDA for treatment of hematopoietic acute radiation syndrome (H-ARS). The UCLA CMCR has recently identified a novel group of small molecules from high throughput screening (HTS) for inhibitors of radiation-induced apoptosis. The lead compound dramatically decreases mortality from H-ARS in mice. To elucidate the mechanism of action for the lead compound, we utilized an emerging target identification approach based on thermal stability shift upon ligand binding (i.e. thermal proteome profiling or TPP). Data from TPP experiments proposed hypothetical targets for the lead compound, which can later be validated by protein-ligand binding studies and other means. |
| 일반주제명 | Chemistry. Biochemistry. |
| 언어 | 영어 |
| 바로가기 | 
: 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |
